Valuation: Becton, Dickinson and Company

Market Cap 46.4B 40.45B 37.76B 34.71B 65.14B 4,438B 66.69B 448B 175B 2,199B 174B 170B 7,582B P/E 2026 *
36.7x
P/E 2027 * 23.9x
Enterprise Value 62.59B 54.57B 50.94B 46.82B 87.88B 5,987B 89.96B 604B 236B 2,967B 235B 230B 10,227B EV / Sales 2026 *
3.26x
EV / Sales 2027 * 3.05x
Free-Float
74.04%
Yield 2026 *
2.33%
Yield 2027 * 2.36%
Manager TitleAgeSince
Chief Executive Officer 53 28/01/2020
Director of Finance/CFO 44 05/12/2025
Compliance Officer - 01/02/2023
Director TitleAgeSince
Director/Board Member 75 24/09/2002
Director/Board Member 71 26/07/2010
Chairman 53 28/04/2021
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-5.43% - - 45.83B
+0.68%+8.36%-14.52%-4.20% 187B
+0.76%+6.30%-4.82%-0.80% 111B
-0.30%+5.13%+11.32%+70.78% 62.18B
+0.34%-6.62%+21.84%+49.32% 48.4B
-1.06%+2.53% - - 34.26B
+0.39%+0.52%-16.07%-43.24% 28.88B
+0.20%-6.06%+30.92%-7.66% 23.72B
+1.95%+10.90%+3.66%+2.08% 22.45B
+4.08%+6.34%-8.01%+5.00% 20.63B
Average +0.70%+1.47%+3.04%+8.91% 59.84B
Weighted average by Cap. +0.54%+3.91%-2.58%+9.19%

Financials

2026 *2027 *
Net sales 19.21B 16.75B 15.64B 14.37B 26.97B 1,838B 27.61B 185B 72.43B 911B 72.13B 70.57B 3,139B 19.72B 17.19B 16.05B 14.75B 27.69B 1,886B 28.35B 190B 74.35B 935B 74.05B 72.44B 3,223B
Net income 1.12B 980M 915M 841M 1.58B 108B 1.62B 10.85B 4.24B 53.31B 4.22B 4.13B 184B 1.45B 1.26B 1.18B 1.08B 2.03B 139B 2.08B 13.98B 5.46B 68.69B 5.44B 5.32B 237B
Net Debt 16.19B 14.12B 13.18B 12.11B 22.73B 1,549B 23.27B 156B 61.05B 768B 60.8B 59.48B 2,646B 13.82B 12.04B 11.24B 10.33B 19.4B 1,321B 19.86B 133B 52.09B 655B 51.87B 50.75B 2,257B
Logo Becton, Dickinson and Company
Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical management systems (52.4%): medication delivery systems, pharmaceutical systems, advanced patient monitoring systems, etc.; - interventional medical equipment (23.9%): surgical instruments, urological care products, etc.; - diagnostic materials and clinical research and development tools (23.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, tools for studying genes and culturing cells, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (58.6%), Europe/Middle East/Africa (21.6%), Asia (14.2%) and other (5.6%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
168.40USD
Average target price
180.25USD
Spread / Average Target
+7.04%

Quarterly revenue - Rate of surprise